STOCKHOLM, Feb. 18, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as […]
Tag: BioArctic
Leqembi® sales reaches €200 million
STOCKHOLM, Feb. 18, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as […]
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024
STOCKHOLM, Nov. 8, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. […]
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024
STOCKHOLM, Nov. 7, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. […]
Invitation to presentation of BioArctic’s third quarter report for July
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ — BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company’s third quarter report for July – September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET. In […]
